Your browser is no longer supported. Please, upgrade your browser.
ESPR Esperion Therapeutics, Inc. monthly Stock Chart
Esperion Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.86 Insider Own0.40% Shs Outstand27.83M Perf Week-8.47%
Market Cap799.52M Forward P/E- EPS next Y-11.72 Insider Trans168.98% Shs Float27.60M Perf Month-11.38%
Income-101.00M PEG- EPS next Q-2.82 Inst Own- Short Float36.45% Perf Quarter-16.81%
Sales218.90M P/S3.65 EPS this Y52.50% Inst Trans-0.65% Short Ratio15.76 Perf Half Y-35.76%
Book/sh0.32 P/B84.44 EPS next Y-183.10% ROA-41.40% Target Price- Perf Year-47.85%
Cash/sh7.29 P/C3.71 EPS next 5Y28.30% ROE-629.90% 52W Range23.90 - 76.98 Perf YTD-54.69%
Dividend- P/FCF- EPS past 5Y-10.10% ROI-467.80% 52W High-64.90% Beta1.62
Dividend %- Quick Ratio3.10 Sales past 5Y- Gross Margin99.70% 52W Low13.05% ATR1.71
Employees193 Current Ratio3.20 Sales Q/Q280.00% Oper. Margin-38.80% RSI (14)39.68 Volatility4.89% 6.33%
OptionableYes Debt/Eq0.00 EPS Q/Q-22.00% Profit Margin-46.20% Rel Volume0.51 Prev Close26.98
ShortableYes LT Debt/Eq0.00 EarningsNov 02 AMC Payout- Avg Volume638.43K Price27.02
Recom1.90 SMA20-3.81% SMA50-15.71% SMA200-32.29% Volume327,055 Change0.15%
Nov-10-20Upgrade Credit Suisse Neutral → Outperform $45
Sep-29-20Resumed JP Morgan Underweight $35
Aug-11-20Downgrade Credit Suisse Outperform → Neutral $83 → $45
Apr-01-20Resumed BofA/Merrill Buy $50
Mar-17-20Upgrade Citigroup Neutral → Buy
Feb-24-20Downgrade Northland Capital Outperform → Market Perform $60
Feb-14-20Downgrade Citigroup Buy → Neutral $82
Sep-16-19Upgrade Goldman Sell → Neutral $55 → $45
May-29-19Downgrade Goldman Neutral → Sell
May-06-19Upgrade BofA/Merrill Underperform → Neutral
Apr-26-19Upgrade Goldman Sell → Neutral $50
Mar-13-19Upgrade JP Morgan Underweight → Neutral $38 → $47
Jan-07-19Reiterated Needham Strong Buy $94 → $114
Dec-13-18Initiated Goldman Sell $45
Oct-29-18Upgrade Northland Capital Market Perform → Outperform
Oct-16-18Initiated BTIG Research Buy $82
Aug-17-18Upgrade Citigroup Neutral → Buy
Jul-11-18Downgrade Northland Capital Outperform → Market Perform
May-03-18Downgrade JP Morgan Neutral → Underweight $41
May-02-18Downgrade BofA/Merrill Buy → Underperform
Nov-13-20 09:15AM  
Nov-12-20 06:17AM  
Nov-10-20 04:30PM  
Nov-06-20 05:00PM  
Nov-04-20 06:15AM  
Nov-03-20 09:36AM  
Nov-02-20 11:31PM  
Oct-27-20 08:00AM  
Oct-26-20 12:31PM  
Oct-19-20 08:00AM  
Oct-13-20 03:04PM  
Oct-07-20 08:00AM  
Sep-28-20 04:06PM  
Sep-22-20 08:56AM  
Sep-02-20 08:41AM  
Aug-26-20 09:07AM  
Aug-21-20 04:05PM  
Aug-11-20 11:10AM  
Aug-10-20 05:15PM  
Aug-07-20 09:27AM  
Aug-06-20 10:05AM  
Aug-03-20 07:26AM  
Jul-16-20 07:16PM  
Jul-01-20 11:12AM  
Jun-23-20 11:42AM  
Jun-22-20 07:00AM  
Jun-16-20 03:09PM  
Jun-14-20 09:30AM  
Jun-12-20 10:20AM  
Jun-08-20 08:00AM  
Jun-05-20 11:31AM  
Jun-04-20 12:00PM  
May-27-20 08:00AM  
May-15-20 06:00PM  
May-08-20 02:49PM  
May-07-20 11:47AM  
May-06-20 06:55PM  
Apr-30-20 08:00AM  
Apr-21-20 07:01AM  
Apr-20-20 07:00AM  
Apr-18-20 10:59AM  
Apr-09-20 08:00AM  
Apr-07-20 10:43AM  
Apr-06-20 07:05AM  
Apr-05-20 08:26AM  
Mar-30-20 04:15PM  
Mar-28-20 11:30AM  
Mar-23-20 07:30AM  
Mar-18-20 07:30AM  
Feb-28-20 04:15PM  
Feb-27-20 10:15AM  
Feb-26-20 05:30PM  
Feb-21-20 04:38PM  
Feb-16-20 03:03PM  
Feb-03-20 01:30PM  
Jan-31-20 07:02AM  
Jan-27-20 12:20PM  
Jan-07-20 07:30AM  
Jan-03-20 04:15PM  
Dec-12-19 11:59AM  
Dec-06-19 11:31AM  
Nov-28-19 07:09AM  
Nov-22-19 06:30PM  
Nov-19-19 09:13AM  
Nov-17-19 03:05PM  
Nov-12-19 11:05AM  
Nov-10-19 07:56AM  
Nov-09-19 09:26AM  
Nov-07-19 11:04AM  
Nov-06-19 08:45AM  
Nov-04-19 07:30AM  
Oct-29-19 07:30AM  
Oct-28-19 05:15PM  
Oct-25-19 10:00AM  
Oct-04-19 08:34AM  
Sep-09-19 10:57AM  
Sep-07-19 09:30AM  
Sep-06-19 06:15PM  
Aug-30-19 04:15PM  
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol in the United States. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BIOTECH TARGET N V10% OwnerNov 03Buy25.31200,0005,062,1203,947,964Nov 04 04:37 PM
MAYLEBEN TIMOTHY MPresident & CEOMar 11Buy43.002,500107,500111,998Mar 12 07:34 AM
MAYLEBEN TIMOTHY MPresident & CEOFeb 28Buy49.005,000245,000109,498Mar 02 06:16 AM
BIOTECH TARGET N V10% OwnerJan 23Buy52.1220,0001,042,3983,747,964Jan 27 12:51 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 All Rights Reserved.